Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) [Phase 2]

View source ↗

Summary

A Phase 2 study of Intismeran Autogene (V940) in combination with BCG for bladder cancer is currently recruiting, targeting non-muscle-invasive bladder cancer i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• Intismeran Autogene (V940) (V940)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms | Phase 2 | Status: RECRUITING